ValuEngine Upgrades BioTelemetry (BEAT) to Strong-Buy

ValuEngine upgraded shares of BioTelemetry (NASDAQ:BEAT) from a buy rating to a strong-buy rating in a report issued on Monday, February 4th.

A number of other brokerages have also recently weighed in on BEAT. Zacks Investment Research cut BioTelemetry from a buy rating to a hold rating in a research report on Monday, February 4th. BidaskClub upgraded BioTelemetry from a buy rating to a strong-buy rating in a research report on Friday, January 11th. Finally, Raymond James dropped their price target on BioTelemetry from $66.00 to $64.00 and set an outperform rating on the stock in a research report on Wednesday, October 31st. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $75.67.

NASDAQ:BEAT traded down $1.45 during trading hours on Monday, reaching $73.27. 1,112,078 shares of the stock were exchanged, compared to its average volume of 652,799. The company has a quick ratio of 2.50, a current ratio of 2.68 and a debt-to-equity ratio of 0.66. BioTelemetry has a 52 week low of $29.85 and a 52 week high of $80.92. The company has a market cap of $2.44 billion, a PE ratio of 37.77, a P/E/G ratio of 3.73 and a beta of 1.75.

BioTelemetry (NASDAQ:BEAT) last released its earnings results on Thursday, February 21st. The medical research company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.13. BioTelemetry had a return on equity of 25.25% and a net margin of 10.72%. The company had revenue of $103.60 million for the quarter, compared to the consensus estimate of $102.84 million. During the same quarter last year, the business posted $0.32 EPS. BioTelemetry’s quarterly revenue was up 13.0% compared to the same quarter last year. As a group, sell-side analysts expect that BioTelemetry will post 1.86 EPS for the current fiscal year.

In related news, VP Heather C. Getz sold 10,590 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $70.41, for a total value of $745,641.90. Following the sale, the vice president now directly owns 80,661 shares in the company, valued at approximately $5,679,341.01. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Heather C. Getz sold 8,236 shares of the firm’s stock in a transaction that occurred on Thursday, January 17th. The shares were sold at an average price of $70.01, for a total value of $576,602.36. Following the completion of the sale, the vice president now owns 88,797 shares in the company, valued at $6,216,677.97. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 177,198 shares of company stock worth $12,419,736. 8.30% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of BEAT. BlackRock Inc. increased its position in shares of BioTelemetry by 7.8% during the 3rd quarter. BlackRock Inc. now owns 4,957,817 shares of the medical research company’s stock valued at $319,531,000 after purchasing an additional 360,529 shares during the period. Loomis Sayles & Co. L P acquired a new position in shares of BioTelemetry during the 3rd quarter valued at $23,211,000. Fuller & Thaler Asset Management Inc. acquired a new position in shares of BioTelemetry during the 3rd quarter valued at $9,947,000. Legal & General Group Plc increased its position in shares of BioTelemetry by 213.4% during the 4th quarter. Legal & General Group Plc now owns 219,499 shares of the medical research company’s stock valued at $13,054,000 after purchasing an additional 149,453 shares during the period. Finally, Credit Suisse AG boosted its stake in shares of BioTelemetry by 18.2% during the 3rd quarter. Credit Suisse AG now owns 826,222 shares of the medical research company’s stock worth $53,250,000 after acquiring an additional 127,195 shares in the last quarter. Institutional investors own 87.43% of the company’s stock.

About BioTelemetry

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Featured Story: Net Margin – Understanding the Different Kinds of Profit

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.